Sex-specific risk assessment of PFHxS using a physiologically based pharmacokinetic model
- 16 November 2017
- journal article
- research article
- Published by Springer Nature in Archives of Toxicology
- Vol. 92 (3) , 1113-1131
Abstract
Perfluorohexanesulfonate (PFHxS), which belongs to the group of perfluoroalkyl and polyfluoroalkyl substances (PFASs), has been extensively used in industry and subsequently detected in the environment. Its use may be problematic, as PFHxS is known to induce neuronal cell death, and has been associated with early onset menopause in women and with attention deficit/hyperactivity disorder. Due to these impending issues, the aim of this study is to develop and evaluate a physiologically based pharmacokinetic (PBPK) model for PFHxS in male and female rats, and apply this to a human health risk assessment. We conducted this study in vivo after the oral or intravenous administration of PFHxS in male (dose of 10 mg/kg) and female rats (dose of 0.5–10 mg/kg). The biological samples consisted of plasma, nine tissues, urine, and feces. We analyzed the sample using ultra-liquid chromatography coupled tandem mass spectrometry (UPLC–MS/MS). Our findings showed the tissue-plasma partition coefficients for PFHxS were highest in the liver. The predicted rat plasma and tissue concentrations using a simulation fitted well with the observed values. We extrapolated the PBPK model in male and female rats to a human PBPK model of PFHxS based on human physiological parameters. The reference doses of 0.711 µg/kg/day (male) and 0.159 µg/kg/day (female) and external doses of 0.007 µg/kg/day (male) and 0.006 µg/kg/day (female) for human risk assessment were estimated using Korean biomonitoring values. This study provides valuable insight into human health risk assessment regarding PFHxS exposure.Keywords
Funding Information
- Ministry of Food and Drug Safety (14162MFDS703, 17162MFDS117)
This publication has 56 references indexed in Scilit:
- Biomonitoring of Perfluoroalkyl Acids in Human Urine and Estimates of Biological Half-LifeEnvironmental Science & Technology, 2013
- Serum Perfluorinated Compound Concentration and Attention Deficit/Hyperactivity Disorder in Children 5–18 Years of AgeEnvironmental Health Perspectives, 2011
- Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published DataThe AAPS Journal, 2011
- Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK modelRegulatory Toxicology and Pharmacology, 2011
- Characterization of Cellular Uptake of Perfluorooctanoate via Organic Anion-Transporting Polypeptide 1A2, Organic Anion Transporter 4, and Urate Transporter 1 for Their Potential Roles in Mediating Human Renal Reabsorption of PerfluorocarboxylatesToxicological Sciences, 2010
- PFCs and Cholesterol: A Sticky ConnectionEnvironmental Health Perspectives, 2010
- Roles of Rat Renal Organic Anion Transporters in Transporting Perfluorinated Carboxylates with Different Chain LengthsToxicological Sciences, 2009
- To scale or not to scale: the principles of dose extrapolationBritish Journal of Pharmacology, 2009
- High Lipophilicity of Perfluoroalkyl Carboxylate and Sulfonate: Implications for Their Membrane PermeabilityJournal of the American Chemical Society, 2009
- Half-Life of Serum Elimination of Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production WorkersEnvironmental Health Perspectives, 2007